NOVIGENIX SA

History

Year	Detail
2014	Novigenix SA was founded in 2014. It is a Swiss company that specializes in precision medicine and molecular diagnostics.
2019	The company collaborated with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology. The test measures the response in patients with neuroendocrine tumors (NET) treated with Alpha and Beta Peptide Receptor Radionuclide Therapy (PRRT).
2022	The company signed a Technology License Agreement with Royal Philips to develop new tissue biopsy Prostate cancer (PCa) Immuno-Transcriptomic tests to improve prostate cancer patient outcomes.
2024	The company partnered with IMMUcan consortium for the development of RNA sequencing biomarkers and to advance the understanding of the immune system’s response to checkpoint inhibitors in cancer patients.

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment